Living in remote Alaska limits my ability to participate in new medication studies. Despite my location challenges, I must admit stem cell therapy is a growing interest for me. A recent study shows most of the 24 recipients of stem cell therapy are still in remission three years later with “lasting neurological function improvement” according to JAMA Neurology. Event-free data is 82.8% at two years and 78.4% in three years. To replace other treatment options available, stem cell therapy must demonstrate even higher efficacy rates to offset the risks of death and “lymphomas associated with Epstein-Barr virus.” However, it does show significant results for those with RRMS in the earlier stages. It is not currently recommended for multiple sclerosis, more research is needed and if it comes to market it is years down the road.
“Three Years After Stem Cell Transplant Therapy Most MS Patient Subjects Still in Remission” on http://multiplesclerosisnewstoday.com/2015/01/02/three-years-after-stem-cell-transplant-therapy-most-ms-patient-subjects-still-in-remission/. Image from the same site.